Lambert-Eaton myasthenic syndrome
| Lambert-Eaton Myasthenic Syndrome | |
 | |
|---|---|
| Global view of a neuromuscular junction: 1. Axon 2. Motor end-plate 3. Muscle fiber 4. Myofibril | |
| ICD-10 | G73.1 |
| ICD-9 | 358.1 |
| DiseasesDB | 4030 |
| MeSH | D015624 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Keanu Ngo[2] Synonyms and keywords: Eaton-Lambert syndrome; Lambert-Eaton syndrome; LEMS
Purpose of this microchapter
This Overview orients the reader to Lambert-Eaton myasthenic syndrome (LEMS): what it is, how it presents, the three pillars of diagnosis, the mandatory cancer link, and the outline of treatment and prognosis. It is deliberately high-level. Mechanistic detail, full diagnostic algorithms, drug dosing, and cancer-screening protocols live in their own microchapters (Pathophysiology, Laboratory findings, Other diagnostic studies, Screening, Medical therapy) and are cross-referenced here rather than duplicated.
Definition and core concept
LEMS is a rare, autoimmune disorder of the presynaptic neuromuscular junction caused by antibodies against P/Q-type (CaV2.1) voltage-gated calcium channels (VGCCs) on the motor nerve terminal. Antibody-mediated loss of functional VGCCs reduces depolarization-evoked calcium influx, lowering the quantal release of acetylcholine so that endplate potentials fail to reach the threshold for muscle fiber contraction — producing weakness.[1][2] The estimated incidence is approximately 0.17–0.6 cases per million per year, with a prevalence of about 2.3–3.8 per million, making LEMS far less common than myasthenia gravis; these figures are likely underestimates given frequent initial misdiagnosis.[3][2][4]
Two forms exist and drive prognosis and workup:
- Paraneoplastic (cancer-associated) LEMS — approximately 50–60% of cases, almost always small cell lung cancer (SCLC); rarely other tumors. The same VGCC antigen expressed on tumor cells triggers the cross-reacting antibody response. Conversely, about 3–4% of unselected patients with SCLC are found to have LEMS, underscoring the tight bidirectional link between the two conditions.[3][2]
- Non-tumor / idiopathic LEMS (NT-LEMS) — the remainder, associated with other autoimmunity and, in many patients, an HLA-B8-DR3 background (covered in Causes/Etiology).
Clinical hallmark: the classic triad
LEMS presents with a clinical triad:[5]
- Proximal muscle weakness, leg-predominant, typically the first symptom (~80%), spreading proximal-to-distal and caudal-to-cranial with increasing severity.
- Autonomic dysfunction — most commonly dry mouth; also orthostatic intolerance, constipation, and erectile dysfunction.
- Reduced or absent deep tendon reflexes, often with post-activation facilitation (transient return of reflexes/strength after brief exercise).
A useful bedside discriminator from myasthenia gravis: LEMS weakness tends to briefly improve after sustained contraction (post-exercise facilitation, the morning "warm-up" phenomenon), whereas myasthenic weakness worsens with activity. Isolated ocular weakness is rare in LEMS.[4]
Three-pronged diagnosis (summary)
Diagnosis rests on the convergence of clinical features, electrophysiology, and serology; details and cutoffs belong to the Laboratory findings and Other diagnostic studies microchapters.[2]
- Serology — anti–P/Q-type VGCC antibodies are present in ~85–95% of patients. Anti-SOX1 antibodies favor an underlying SCLC. Seronegative LEMS occurs, so a negative antibody test does not exclude the diagnosis.[3][4]
- Electrophysiology (RNS/EMG) — low baseline compound muscle action potential (CMAP), a decrement (>10%) at low-frequency (2–5 Hz) repetitive nerve stimulation, and a large increment (>60–100%) after high-frequency stimulation or brief maximal exercise. Post-exercise facilitation is the hallmark presynaptic sign.[5] By contrast, prominent or isolated ocular weakness is atypical for LEMS and should prompt reconsideration of myasthenia gravis.[5]
The mandatory cancer link
A new LEMS diagnosis is a clinical warning sign for SCLC and must trigger rigorous oncologic screening and surveillance.[2] Neurologic symptoms precede the cancer diagnosis in nearly all paraneoplastic cases, and SCLC is detected within 12 months in over 95% of patients using intensive screening. The validated DELTA-P score — age at onset, smoking status at onset, bulbar involvement, weight loss, erectile dysfunction, and Karnofsky performance status — stratifies SCLC risk at diagnosis; weight loss ≥5%, tobacco use at onset, and age ≥50 were the independent predictors in prospective validation.[6][7] Protocol and imaging specifics belong to the Screening microchapter.
Treatment framework (summary)
Management has three parallel components; sequencing and dosing are detailed in Medical therapy:
- Symptomatic therapy — amifampridine (3,4-diaminopyridine) is first-line and FDA-approved for LEMS in adults and children ≥6 years; it is a broad-spectrum potassium-channel blocker thought to prolong presynaptic depolarization and enhance acetylcholine release, though the FDA label notes the precise mechanism has not been fully elucidated.[8][9] Pyridostigmine may be added as an adjunct.
- Immunotherapy — for inadequate response or flares: prednisone plus azathioprine, IVIG, or plasma exchange.[10][5]
- Oncologic treatment — when a tumor is found, treating the SCLC takes priority and often improves the neurologic syndrome.[11]
Prognosis (summary)
Prognosis diverges by subtype. NT-LEMS carries a normal life expectancy, though complete remission is uncommon. In SCLC-LEMS, tumor progression determines survival, but outcomes are paradoxically better than in SCLC without LEMS (median survival ~17 vs ~7 months in one registry comparison), likely reflecting earlier cancer detection and antitumor immunity.[7]
References
- ↑ Huijbers MG, Marx A, Plomp JJ, et al. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022.
- ↑ 2.0 2.1 2.2 2.3 2.4 Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017.
- ↑ 3.0 3.1 3.2 Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022.
- ↑ 4.0 4.1 4.2 Zarhin D, Kolb H, Gadoth A. Gasping for strength. N Engl J Med. 2025.
- ↑ 5.0 5.1 5.2 5.3 Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011.
- ↑ Maddison P, Lipka AF, Gozzard P, et al. Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Sci Rep. 2020.
- ↑ 7.0 7.1 Verschuuren JJ, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022.
- ↑ Firdapse (amifampridine) FDA prescribing information. 2024.
- ↑ Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020.
- ↑ Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010.
- ↑ Chen T. Clinical reasoning: a 68-year-old man with proximal weakness and seizures. Neurology. 2021.
Template:PNS diseases of the nervous system Template:WH Template:WikiDoc Sources